Jyong Biotech Business Summary

Jyong Biotech Ltd. (MENS) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative, plant-derived botanical drugs targeting urinary system diseases. The company generates revenue through a hybrid model of direct commercialization, regional licensing, and co-commercialization agreements, notably leveraging partnerships in South Korea and Vietnam to scale its pipeline. Its primary business segments are categorized by therapeutic indication: benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) led by its flagship candidate MCS-2 (Botreso®), prostate cancer prevention (PCP) featuring the Phase II candidate MCS-8, and interstitial cystitis (IC). Within the competitive landscape, Jyong Biotech contends with pharmaceutical firms such as ProKidney (PROK), Altimmune (ALT), and Keros Therapeutics (KROS); however, it distinguishes itself by focusing exclusively on botanical-based urological therapies, positioning itself as a science-driven niche leader in the plant-derived drug market. The leadership team is anchored by founder, Chairwoman, and CEO Fu-Feng Kuo, who brings over 30 years of R&D experience in botanical products and previously founded Health Ever Bio-Tech. The executive suite was recently strengthened by the February 2026 appointment of Chief Financial Officer Wei (Vivi) Zhang, an Oxford MBA with extensive capital markets experience from her tenure at Global Mofy AI Limited. Technical operations are overseen by Chief Technology Officer Dr. Fenglin Hsu, a specialist in natural medicinal chemistry and former professor at the China Industrial & Commercial Research Institute, alongside Chief Science Officer Dr. Wanwen Su. While the company maintains a high level of insider ownership—with CEO Fu-Feng Kuo holding approximately 33% of outstanding shares—notable institutional presence includes BlackRock Asset Management Ireland Ltd., reflecting a concentrated governance structure focused on long-term clinical validation.